Curetis to Present
at Key Investor and Scientific Conferences in the Fourth Quarter
2017
Amsterdam, the
Netherlands, and Holzgerlingen, Germany, October 6, 2017 --
published at 08:00 am CET -- Curetis N.V. (the
"Company" and, together with Curetis GmbH,
"Curetis"), a developer of next-level
molecular diagnostic solutions, today announced its participation
in several industry conferences in the fourth quarter of 2017. The
respective presentations will be made available on the company's
website.
October
Large and Midcap Conference
2017, October 4-5, 2017 - Paris, France: One-on-one
meetings.
ID Week 2017, October 4-8, 2017 - San Diego,
CA, USA: Booth 637.
CRIOAC 2017 CRIOAC,
October 19-20, 2017 - Tours, France.
DKOU
2017, October 23-27, 2017 - Berlin, Germany: Hall 2.2b, booth
68.
November
Biotech & Money Inv€$tival
Showcase Event, November 14, 2017 - London, UK: One-on-one
meetings and presentation.
Jefferies Global Healthcare
Conference 2017, November 15-16, 2017 - London, UK: One-on-one
meetings.
AMP 2017, November 16-19, 2017 - Salt Lake
City, UT, USA: Booth 1801.
###
About Curetis
Founded in 2007, Curetis is a molecular diagnostics company which
focuses on the development and commercialization of reliable, fast
and cost-effective products for diagnosing severe infectious
diseases. The diagnostic solutions of Curetis enable rapid
multi-parameter pathogen and antibiotic resistance marker detection
in only a few hours, a process that today can take up to days or
even weeks with other techniques.
To date, Curetis has raised EUR
44.3 million in an IPO on Euronext Amsterdam and Euronext Brussels
and private equity funds of over EUR 63.5 million. Furthermore,
Curetis has entered into a debt financing facility with EIB for up
to EUR 25 million. The company is based in Holzgerlingen near
Stuttgart, Germany. Curetis collaborates with Heraeus Medical,
pharmaceutical companies, and has entered into several
international distribution agreements covering many countries
across Europe, the Middle East and Asia.
In 2017, Curetis established Ares
Genetics GmbH, a wholly-owned subsidiary of Curetis GmbH in Vienna,
Austria. Ares Genetics is dedicated to maximize the R&D and
related scientific and business opportunities of the GEAR assets
acquired in 2016 for the entire Curetis Group.
For further information, please
visit www.curetis.com.
Legal Disclaimer
This document constitutes neither an offer to buy nor to subscribe
securities and neither this document nor any part of it should form
the basis of any investment decision in Curetis.
The information contained in this press release
has been carefully prepared. However, Curetis bears and assumes no
liability of whatever kind for the correctness and completeness of
the information provided herein. Curetis does not assume an
obligation of whatever kind to update or correct information
contained in this press release whether as a result of new
information, future events or for other reasons.
This press release includes statements that are,
or may be deemed to be, "forward-looking statements". These
forward-looking statements can be identified by the use of
forward-looking terminology, including the terms "believes",
"estimates", "anticipates", "expects", "intends", "may", "will", or
"should", and include statements Curetis makes concerning the
intended results of its strategy. By their nature, forward-looking
statements involve risks and uncertainties and readers are
cautioned that any such forward-looking statements are not
guarantees of future performance. Curetis' actual results may
differ materially from those predicted by the forward-looking
statements. Curetis undertakes no obligation to publicly update or
revise forward-looking statements, except as may be required by
law.
Contact details
Curetis
Max-Eyth-Str. 42
71088 Holzgerlingen, Germany
Tel. +49 7031 49195-10
pr@curetis.com or ir@curetis.com
www.curetis.com - www.unyvero.com
International Media &
Investor Inquiries
akampion
Dr. Ludger Wess / Ines-Regina Buth
Managing Partners
info(@)akampion.com
Tel. +49 40 88 16 59 64
Tel. +49 30 23 63 27 68
U.S. Media & Investor
Inquiries
The Ruth Group
Lee Roth
lroth@theruthgroup.com
Tel. +1 646 536 7012
Curetis_Logo
20171006_Curetis_PR_EN_Q4 Conferences